Patents Assigned to Merus B.V.
-
Publication number: 20240164354Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 26, 2024Publication date: May 23, 2024Applicant: Merus B.V.Inventors: Ton LOGTENBERG, Rui Daniel PINTO, Erwin HOUTZAGER
-
Publication number: 20160238600Abstract: Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: ApplicationFiled: April 27, 2016Publication date: August 18, 2016Applicant: Merus B.V.Inventors: Hendricus Renerus Hoogenboom, Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Patent number: 9358286Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: November 15, 2013Date of Patent: June 7, 2016Assignee: Merus B.V.Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Publication number: 20160130367Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: ApplicationFiled: September 16, 2015Publication date: May 12, 2016Applicant: Merus B.V.Inventors: Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
-
Patent number: 9303081Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: March 4, 2011Date of Patent: April 5, 2016Assignee: Merus B.V.Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 9248181Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: April 19, 2013Date of Patent: February 2, 2016Assignee: Merus B.V.Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 9248182Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: April 19, 2013Date of Patent: February 2, 2016Assignee: Merus B.V.Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 9012371Abstract: Described are methods for producing libraries of cells expressing at least two separate single polypeptide chain binding proteins, in which the binding proteins have different target epitopes. Such libraries are made by integration of the nucleic acid sequences encoding the polypeptide chains into the genome of the host cell, and selecting for cells that have successfully integrated these nucleic acids. The selected cells are preferably subjected to a cloning step. Mixtures of binding proteins are produced without having to individually produce each of the components of the mixture. A library of cells wherein essentially each cell encodes at least two single polypeptide chain binding proteins having different target epitopes is also herewith provided, as well as methods for producing a composition comprising at least two separate single polypeptide chain binding proteins having different target epitopes.Type: GrantFiled: October 5, 2011Date of Patent: April 21, 2015Assignee: Merus B.V.Inventors: Ton Logtenberg, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Publication number: 20140140999Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: ApplicationFiled: November 15, 2013Publication date: May 22, 2014Applicant: MERUS B.V.Inventors: Cornelis A. DE KRUIF, Linda Johanna Aleida HENDRIKS, Ton LOGTENBERG
-
Publication number: 20140120096Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: ApplicationFiled: September 27, 2013Publication date: May 1, 2014Applicant: MERUS B.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO, Ton LOGTENBERG
-
Publication number: 20140072579Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: ApplicationFiled: April 19, 2013Publication date: March 13, 2014Applicant: Merus B.V.Inventor: Merus B.V.
-
Publication number: 20130336981Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: ApplicationFiled: April 19, 2013Publication date: December 19, 2013Applicant: Merus B.V.Inventors: Cornelis A. de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Publication number: 20130243773Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: Merus B.V.Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Publication number: 20130145484Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 25, 2013Publication date: June 6, 2013Applicant: MERUS B.V.Inventor: MERUS B.V.
-
Patent number: 8268756Abstract: Described are methods for producing libraries of cells expressing at least two separate single polypeptide chain binding proteins, in which the binding proteins have different target epitopes. Such libraries are made by integration of the nucleic acid sequences encoding the polypeptide chains into the genome of the host cell, and selecting for cells that have successfully integrated these nucleic acids. The selected cells are preferably subjected to a cloning step. Mixtures of binding proteins are produced without having to individually produce each of the components of the mixture. A library of cells wherein essentially each cell encodes at least two single polypeptide chain binding proteins having different target epitopes is also herewith provided, as well as methods for producing a composition comprising at least two separate single polypeptide chain binding proteins having different target epitopes.Type: GrantFiled: July 20, 2006Date of Patent: September 18, 2012Assignee: Merus B.V.Inventors: Ton Logtenberg, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Patent number: 7932360Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: November 6, 2006Date of Patent: April 26, 2011Assignee: Merus B.V.Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 7927834Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: July 29, 2008Date of Patent: April 19, 2011Assignee: Merus B.V.Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Publication number: 20100146647Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: October 19, 2009Publication date: June 10, 2010Applicant: Merus B. V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20100069614Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: June 29, 2009Publication date: March 18, 2010Applicant: Merus B.V.Inventors: Erwin Houtzager, Rui Daniel Pinto, Ton Logtenberg, Mark Throsby
-
Publication number: 20070059766Abstract: Described are methods for producing libraries of cells expressing at least two separate single polypeptide chain binding proteins, in which the binding proteins have different target epitopes. Such libraries are made by integration of the nucleic acid sequences encoding the polypeptide chains into the genome of the host cell, and selecting for cells that have successfully integrated these nucleic acids. The selected cells are preferably subjected to a cloning step. Mixtures of binding proteins are produced without having to individually produce each of the components of the mixture. A library of cells wherein essentially each cell encodes at least two single polypeptide chain binding proteins having different target epitopes is also herewith provided, as well as methods for producing a composition comprising at least two separate single polypeptide chain binding proteins having different target epitopes.Type: ApplicationFiled: July 20, 2006Publication date: March 15, 2007Applicant: Merus B.V.Inventors: Ton Logtenberg, Hendricus Renerus Hoogenboom